Hong Kong-listed Metis TechBio said on Monday it has entered into a collaboration agreement with Eli Lilly worth up to $1.1 billion to research and develop tissue-specific drug delivery technologies.
No comments yet.
Hong Kong-listed Metis TechBio said on Monday it has entered into a collaboration agreement with Eli Lilly worth up to $1.1 billion to research and develop tissue-specific drug delivery technologies.
No comments yet.
Log in or sign up to comment.